CURRENT RECRUITING TRIALS
CONTACT US
(514) 398-5500 or neurocog-cru.neuro@mcgill.ca
University College London GENFI3 (Frontotemporal Dementia)
Genetic Frontotemporal Dementia Initiative
The aim of the study is to understand more about genetic FTD, particularly in those who have mutations in the progranulin (GRN), microtubule-associated protein tau (MAPT) and chromosome 9 open reading frame 72 (C9ORF72) genes. There are now promising avenues for treatment of these disorders but we still do not know when drugs should be started or how we should measure the response to treatment.
GENFI investigates both people who have developed symptoms and also people who have a risk of developing symptoms in the future because they carry an abnormal genetic mutation. By studying these individuals who are destined to develop the disease later in life we can understand the development from the very earliest changes. The key objectives of GENFI are therefore to develop markers which help identify the disease at its earliest stage as well as markers that allow the progression of the disease to be tracked.
The eventual aim will be to use these markers in future clinical trials of drugs in genetic FTD.
UPCOMING TRIALS
Arrowhead ARO-MAPT-SC 1001 (Early Alzheimer's Disease)
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer’s Disease
Posit Science INHANCE-MCI (Mild Cognitive Impairment)
A neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).
The primary objective of this study is to evaluate will evaluate the impact of speed training to change cholinergic signaling, cognitive performance, and functional abilities in patients with MCI, as evidenced by [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET) and standard measures of cognition and function.
The investigators will employ a prospective, double-blind, parallel-arm, active-controlled, randomized clinical trial in patients with clinically-defined mild cognitive impairment aged 65 and above with a baseline MoCA of 18-26 inclusive.
Roche BP45770 MEADOW (early Alzheimer's Disease)
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer’s Disease.Â
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
ACTIVE (NOT RECRUITING) TRIALS
Alnylam ALN APP-001 (Early Alzheimer's Disease)
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single intrathecal (IT) doses of ALN-APP in adult patients with early-onset Alzheimer’s Disease (EOAD). Â
Biogen 247AD201 CELIA (Maladie d'Alzheimer)
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most.
To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB.
- Clinicians use the CDR-SB to measure several categories of dementia symptoms.
- The results for each category are added together for a total score. Lower scores are better.
Researchers will also learn more about the safety of BIIB080.
Ionis ION717-C62 (Prion Disease)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
This is a first-in-human, randomized, multi-center study in participants with prion disease. Eligible participants will receive ION717 and placebo. The study will consist of a screening period of up to 6 weeks, a 30-week double-blind treatment period, a 70-week open-label extension period and a 32-week post-treatment period. During the double-blind period, the order of ION717 and placebo doses will be randomized and blinded to participants, study sites and the Sponsor. During the open-label extension period, all participants will receive ION717. Multiple dose levels will be tested.
Washington University School of Medicine DIAN-TU-001 (Alzheimer’s Disease)
As part of the DIAN-TU-001 protocol, participants undergo longitudinal assessments that include clinical assessment, cognitive testing, magnetic resonance imaging (MRI) and amyloid and tau positron emission tomography (PET) imaging, and analysis of blood and cerebrospinal fluid (CSF).
–
THE TEAM
Dr Simon Ducharme
Principal Investigator
Dr M. Pandolfo
Principal Investigator
Celia Sciandra
Clinical Research Coordinator
–
–
Dr de Villers-Sidani
Principal Investigator
Elisabeth Sylvain
Team Lead
Ting Ting Liu
Clinical Research Coord